Clinicaltrials.gov identifier:
NCT03805919
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
Study Contact Information:
Anna Couvillon, Nurse Practitioner
By phone: (240) 858-3148
or by email
Men at High Genetic Risk for Prostate Cancer
About the Study
The National Cancer Institute opened a clinical trial for cancer screening in men who are at high risk for cancer due to an inherited mutation.
View the study on ClinicalTrials.gov or contact Anna Couvillon, NP at: (240) 858-3148 or by email.
What the Study Entails
- Screening of the every 2 years
- Annual blood test
- Biopsy of the if any MRIs are abnormal
- No cost for study-related tests or procedures
- No cost for travel
- Clinical information will be shared with you and your doctor, if you choose
- Genetic testing is not offered as part of the study
Study Lead Investigator
Fatima Karzai, MD, National Cancer Institute (NCI)
Study Site
The National Institutes of Health (), Clinical Center
Bethesda, MD in the Washington, DC metro area
NIH can cover the cost of travel for participants
- Men, 30 to 75 years old without cancer who have tested positive for (, , , , ), , , HOXB13, , , , , , , , , or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM) mutation.
- Genetic testing is not offered.
- Men who have already been diagnosed with cancer